newsfilter
← Latest News
PR Newswire·

New biomarker data from BEXMAB study at EHA2023

Faron Pharmaceuticals Oy ("Faron" or "the Company") Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress Bexmarilimab mode of action in AML/MDS supported with